Returning guest Dr. Paul Limburg, a gastroenterology consultant at the Mayo Clinic, and CMO for screening at Exact Sciences discusses new data from the Colorectal Cancer and Adenoma Incidence and Mortality model (CRC-AIM) shared as several e-presentations published by Digestive Disease Week (DDW) 2020 that shows the value of Cologuard® (mt-sDNA) as an effective colorectal cancer screening test over fecal immunochemical testing (FIT). The research also highlights the need for improved access to colonoscopy following a positive Cologuard® test or FIT.
Paul J. Limburg, M.D. is a consultant in the Division of Gastroenterology and Hepatology, with a joint appointment in the Division of Preventive, Occupational and Aerospace Medicine. He is a professor of medicine in the College of Medicine, Mayo Clinic and the chief medical officer for screening at Exact Sciences.